NewcelX Ltd.
No enriched coverage for $NCEL in the last 7 days.
No SEC Form 4 filings for $NCEL in the last 30 days.
NewcelX Ltd. (Nasdaq: NCEL) said Brazil’s patent office granted Patent BR 112018010946-0 covering its NCEL-101 cell selection and enrichment manufacturing technology until November 2036. The company links the grant to a recent FDA Type B Pre-IND meeting for NCEL-101 with Eledon’s tegoprubart for type 1 diabetes.
NewcelX Ltd. (Nasdaq: NCEL) appointed Dr. Camillo Ricordi to its Scientific Advisory Board. The move follows the company’s reported successful FDA Type B Pre-IND meeting for NCEL-101, which it says provides a regulatory pathway toward clinical trials. Ricordi will support NewcelX’s type 1 diabetes program and collaboration with Eledon Pharmaceuticals.
NewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).
Recent NCEL coverage spans corporate actions, financial news and regulation.
Patent grant strengthens NCEL-101’s long-dated IP moat in a major Latin American T1D market, supporting valuation and partnering optionality.
Board-level scientific validation plus a stated FDA development pathway can modestly improve perceived execution risk for NCEL-101.
FDA feedback and a defined clinical/IND-enabling pathway reduce regulatory uncertainty for NCEL-101 and can improve near-term sentiment and financing optionality.
The study is supportive scientific validation for AstroRx®/platform, but it is not a new clinical readout or regulatory milestone.
Pre-IND meeting scheduling is a tangible regulatory planning milestone for first-in-human trial execution.
alphai scores every news story that mentions NCEL with an AI model for sentiment and relevance, and aggregates insider trades from NewcelX Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NewcelX Ltd. (Nasdaq: NCEL) said Brazil’s patent office granted Patent BR 112018010946-0 covering its NCEL-101 cell selection and enrichment manufacturing technology until November 2036. The company links the grant to a recent FDA Type B Pre-IND meeting for NCEL-101 with Eledon’s tegoprubart for type 1 diabetes.
4 min readNewcelX Ltd. (Nasdaq: NCEL) appointed Dr. Camillo Ricordi to its Scientific Advisory Board. The move follows the company’s reported successful FDA Type B Pre-IND meeting for NCEL-101, which it says provides a regulatory pathway toward clinical trials. Ricordi will support NewcelX’s type 1 diabetes program and collaboration with Eledon Pharmaceuticals.
3 min readNewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).
3 min readNewcelX Ltd. (Nasdaq: NCEL) said a peer-reviewed Stem Cell Reports study supports its AstroRx® therapy for multiple sclerosis and other chronic demyelinating diseases. The paper, based on in vitro and a lysolecithin-induced demyelination model, reports AstroRx® may enhance myelin debris clearance, sustain pro-repair inflammation, and promote OPC differentiation. AstroRx® previously completed a Phase 1/2a ALS trial.
4 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min read
